(Q46283493)

21 December 2017

title

Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats (English)

1 reference

21 December 2017

author name string

Yanfei L Ma

1

1 reference

21 December 2017

Henry U Bryant

2

1 reference

21 December 2017

Qingqiang Zeng

3

1 reference

21 December 2017

Allen Schmidt

4

1 reference

21 December 2017

Webster S S Jee

5

1 reference

21 December 2017

Masahiko Sato

6

1 reference

21 December 2017

publication date

1 January 2005

1 reference

21 December 2017

Journal of Bone and Mineral Metabolism

published in

1 reference

21 December 2017

volume

23 Suppl

1 reference

21 December 2017

page(s)

62-68

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1007/bf03026325

exact match

0 references

cites work

Anabolic actions of parathyroid hormone on bone

1 reference

12 December 2020

Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques

1 reference

12 December 2020

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

1 reference

12 December 2020

Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)

1 reference

12 December 2020

Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Basic biomechanical measurements of bone: a tutorial

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats

1 reference

12 December 2020

Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).

1 reference

12 December 2020

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

1 reference

12 December 2020

The effects of raloxifene on tibia histomorphometry in ovariectomized rats

1 reference

12 December 2020

New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats

1 reference

12 December 2020

Raloxifene preserves bone strength and bone mass in ovariectomized rats

1 reference

12 December 2020

Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats

1 reference

12 December 2020

Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats

1 reference

12 December 2020

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

12 December 2020

Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation

1 reference

12 December 2020

In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment

1 reference

12 December 2020

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients

1 reference

12 December 2020

Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats

1 reference

12 December 2020

Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure

1 reference

12 December 2020

In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats

1 reference

12 December 2020

Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels

1 reference

12 December 2020

Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats

1 reference

12 December 2020

Anabolic Actions of Parathyroid Hormone on Bone*

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03026325

1 reference

21 December 2017

1 reference

21 December 2017